Hypertension Management in Diabetes: 2018 Update - PubMed (original) (raw)
Hypertension Management in Diabetes: 2018 Update
Pasquale Passarella et al. Diabetes Spectr. 2018 Aug.
Abstract
IN BRIEF Several guidelines and position statements are published to help clinicians manage hypertension in patients with diabetes. Although there is an unequivocal call to treat hypertension in diabetes, professional organizations and experts have differing opinions regarding the most optimal blood pressure targets and treatments to lower vascular risks in the diabetes population. The objective of this article is to summarize the most recent hypertension management guidelines with particular attention to the origins and evidence behind these recommendations.
Figures
FIGURE 1.
Pathway to initial antihypertensive therapy in patients with diabetes. *Use of chlorthalidone or indapamide is preferred. **Can be suggested as first-line therapy in patients with microalbuminuria. BP, blood pressure; UACR, urine albumin-to-creatinine ratio.
Similar articles
- The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
Khan NA, McAlister FA, Campbell NR, Feldman RD, Rabkin S, Mahon J, Lewanczuk R, Zarnke KB, Hemmelgarn B, Lebel M, Levine M, Herbert C; Canadian Hypertension Education Program. Khan NA, et al. Can J Cardiol. 2004 Jan;20(1):41-54. Can J Cardiol. 2004. PMID: 14968142 - The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy.
Khan NA, Hemmelgarn B, Padwal R, Larochelle P, Mahon JL, Lewanczuk RZ, McAlister FA, Rabkin SW, Hill MD, Feldman RD, Schiffrin EL, Campbell NR, Logan AG, Arnold M, Moe G, Campbell TS, Milot A, Stone JA, Jones C, Leiter LA, Ogilvie RI, Herman RJ, Hamet P, Fodor G, Carruthers G, Culleton B, Burns KD, Ruzicka M, deChamplain J, Pylypchuk G, Gledhill N, Petrella R, Boulanger JM, Trudeau L, Hegele RA, Woo V, McFarlane P, Touyz RM, Tobe SW; Canadian Hypertension Education Program. Khan NA, et al. Can J Cardiol. 2007 May 15;23(7):539-50. doi: 10.1016/s0828-282x(07)70798-5. Can J Cardiol. 2007. PMID: 17534460 Free PMC article. - The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy.
Khan NA, McAlister FA, Lewanczuk RZ, Touyz RM, Padwal R, Rabkin SW, Leiter LA, Lebel M, Herbert C, Schiffrin EL, Herman RJ, Hamet P, Fodor G, Carruthers G, Culleton B, DeChamplain J, Pylypchuk G, Logan AG, Gledhill N, Petrella R, Campbell NR, Arnold M, Moe G, Hill MD, Jones C, Larochelle P, Ogilvie RI, Tobe S, Houlden R, Burgess E, Feldman RD; Canadian Hypertension Education Program. Khan NA, et al. Can J Cardiol. 2005 Jun;21(8):657-72. Can J Cardiol. 2005. PMID: 16003449 - Clinical Practice Guideline: Sudden Hearing Loss (Update) Executive Summary.
Chandrasekhar SS, Tsai Do BS, Schwartz SR, Bontempo LJ, Faucett EA, Finestone SA, Hollingsworth DB, Kelley DM, Kmucha ST, Moonis G, Poling GL, Roberts JK, Stachler RJ, Zeitler DM, Corrigan MD, Nnacheta LC, Satterfield L, Monjur TM. Chandrasekhar SS, et al. Otolaryngol Head Neck Surg. 2019 Aug;161(2):195-210. doi: 10.1177/0194599819859883. Otolaryngol Head Neck Surg. 2019. PMID: 31369349 - Are diabetes guidelines truly evidence based?
Bouchonville MF, Matani S, DuBroff JJ, DuBroff RJ. Bouchonville MF, et al. Diabetes Res Clin Pract. 2017 May;127:70-79. doi: 10.1016/j.diabres.2017.02.035. Epub 2017 Mar 7. Diabetes Res Clin Pract. 2017. PMID: 28319804 Review.
Cited by
- Update on Treatment of Hypertension After Renal Transplantation.
Chatzikyrkou C, Schmieder RE, Schiffer M. Chatzikyrkou C, et al. Curr Hypertens Rep. 2021 May 7;23(5):25. doi: 10.1007/s11906-021-01151-8. Curr Hypertens Rep. 2021. PMID: 33961145 Review. - Suboptimal Blood Pressure Control, Associated Factors, and Choice of Antihypertensive Drugs among Type 2 Diabetic Patients at KCMC, Tanzania.
Mbwete GW, Kilonzo KG, Shao ER, Chamba NG. Mbwete GW, et al. J Diabetes Res. 2020 Jul 20;2020:4376251. doi: 10.1155/2020/4376251. eCollection 2020. J Diabetes Res. 2020. PMID: 32775461 Free PMC article. - A Cross-sectional Study to Assess Beta-Cell Function in Individuals with Recently Diagnosed Young-Onset Type 2 Diabetes Mellitus and Its' Complications.
Nagaratnam S, Rajoo S, Bidin MBL, Rahim NSC, Tharmathurai S, Arip M, Ching YM, Foo SH. Nagaratnam S, et al. J ASEAN Fed Endocr Soc. 2023;38(2):20-27. doi: 10.15605/jafes.038.02.13. Epub 2023 Jul 19. J ASEAN Fed Endocr Soc. 2023. PMID: 38045672 Free PMC article. - Nephroprotective Effects of Dapagliflozin in Patients with Type 2 Diabetes.
Iijima Y, Nakayama M, Miwa T, Yakou F, Tomiyama H, Shikuma J, Ito R, Tanaka A, Manda N, Odawara M. Iijima Y, et al. Intern Med. 2023;62(5):681-688. doi: 10.2169/internalmedicine.6685-20. Epub 2023 Mar 1. Intern Med. 2023. PMID: 36858619 Free PMC article. - Pathophysiologic Mechanisms and Potential Biomarkers in Diabetic Kidney Disease.
Jung CY, Yoo TH. Jung CY, et al. Diabetes Metab J. 2022 Mar;46(2):181-197. doi: 10.4093/dmj.2021.0329. Epub 2022 Mar 24. Diabetes Metab J. 2022. PMID: 35385633 Free PMC article. Review.
References
- Centers for Disease Control and Prevention National diabetes statistics report—2017. Available from www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-r.... Accessed 23 December 17
- Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434–444 - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous